#HAE #HaeWarrior #HereditaryAngioedema #ChronicIllnessAwareness #ChronicWarrior #InvisibleIllness #SpoonieLife #HAEStrong #ChronicCondition #MindfulLiving #BioNews #AngioedemaNews

#HAE #HereditaryAngioedema#ChronicIllness #RareDisease #ChronicIllnessCommunity #HolidayStress #ChronicLife #InvisibleIllness #ChronicIllnessWarrior #Spoonie #ChronicIllnessAwareness #MentalHealthMatters #HolidaySeason #ChronicIllnessSupport #BioNews #AngioedemaNews

#HAE #HereditaryAngioedema #HAECommunity #HAEWarrior #HAEAwareness #ChronicIllness #RareDisease #PediatricHAE #Orladeyo #OralProphylaxis #PreventiveTreatment #ChronicIllnessCommunity #CaregiverLife #PatientCare #RareDiseaseCommunity #HealthNews #BioNews #AngioedemaNews

This means more families may have access to a long-term preventive option that doesn’t require infusions or injections, potentially easing some of the day-to-day burden of managing pediatric HAE.

Orladeyo (berotralstat) has earned expanded FDA approval as the only oral prophylactic treatment in the U.S. for children with hereditary angioedema ages 2–11, using a new oral pellet formulation designed with young patients and caregivers in mind.